1hcg › Citations

Structure of human des(1-45) factor Xa at 2.2 A resolution.

Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W
J Mol Biol 232 947-66 (1993)
Related entries: 1apo, 1hgt, 2hgt

Cited: 203 times
EuropePMC logo PMID: 8355279

Abstract

The structure of a large molecular fragment of factor Xa that lacks only a Gla (gamma-carboxyglutamic acid) domain (N-terminal 45 residues) has been solved by X-ray crystallography and refined at 2.2 A resolution to a crystallographic R-value of 0.168. The fragment identity was clearly established by automated Edman degradation. X-ray structure analysis confirmed the biochemical characterization and also revealed that the N-terminal epidermal growth factor (EGF)-like domain is flexibly disordered in crystals. The second EGF module, however, is positionally ordered making contacts with the catalytic domain. The overall folding of the catalytic domain is similar to that of alpha-thrombin, excluding the insertion loops of the latter with respect to simpler serine proteinases. The C-terminal arginine of the A-chain interacts in a substrate-like manner with the S1 specificity site of the active site of a crystallographically neighboring molecule. Based on this interaction and the structure of D-PheProArg methylene-thrombin, a model of the commonly used dansylGluGlyArg methylene inhibitor-factor Xa interaction is proposed. The region of factor Xa corresponding to the fibrinogen recognition site of thrombin has a reversed electrical polarity to the anion binding fibrinogen recognition site of thrombin but possesses a site similar to the Ca2+ binding site of trypsin and other serine proteinases. The structure of the C-terminal EGF domain of factor Xa is the first to be determined crystallographically. Its folding has been comprehensively compared with similar domains determined by NMR. Although the A-chain makes 44 contacts at less than 3.5 A with the catalytic domain, only 16 involve the EGF module. In addition, the A-chain makes 30 intermolecular contacts with a neighboring catalytic domain.

Articles - 1hcg mentioned but not cited (14)

  1. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. Abel R, Young T, Farid R, Berne BJ, Friesner RA. J. Am. Chem. Soc. 130 2817-2831 (2008)
  2. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Persson E, Kjalke M, Olsen OH. Proc. Natl. Acad. Sci. U.S.A. 98 13583-13588 (2001)
  3. Structural basis for chemical inhibition of human blood coagulation factor Xa. Kamata K, Kawamoto H, Honma T, Iwama T, Kim SH. Proc. Natl. Acad. Sci. U.S.A. 95 6630-6635 (1998)
  4. Demonstration of the extrinsic coagulation pathway in teleostei: identification of zebrafish coagulation factor VII. Sheehan J, Templer M, Gregory M, Hanumanthaiah R, Troyer D, Phan T, Thankavel B, Jagadeeswaran P. Proc. Natl. Acad. Sci. U.S.A. 98 8768-8773 (2001)
  5. Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Lechtenberg BC, Murray-Rust TA, Johnson DJ, Adams TE, Krishnaswamy S, Camire RM, Huntington JA. Blood 122 2777-2783 (2013)
  6. Protein subunit interfaces: heterodimers versus homodimers. Zhanhua C, Gan JG, Lei L, Sakharkar MK, Kangueane P. Bioinformation 1 28-39 (2005)
  7. A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. Duffy MR, Bradshaw AC, Parker AL, McVey JH, Baker AH. J. Virol. 85 10914-10919 (2011)
  8. New enzyme lineages by subdomain shuffling. Hopfner KP, Kopetzki E, Kresse GB, Bode W, Huber R, Engh RA. Proc. Natl. Acad. Sci. U.S.A. 95 9813-9818 (1998)
  9. Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. Huang X, Dementiev A, Olson ST, Gettins PG. J. Biol. Chem. 285 20399-20409 (2010)
  10. Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes. Irons EE, Flatt JW, Flatt JW, Flatt JW, Doronin K, Fox TL, Acchione M, Stewart PL, Shayakhmetov DM. J. Virol. 87 9610-9619 (2013)
  11. Protein pharmacophore selection using hydration-site analysis. Hu B, Lill MA. J Chem Inf Model 52 1046-1060 (2012)
  12. Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions. Beirnaert E, Desmyter A, Spinelli S, Lauwereys M, Aarden L, Dreier T, Loris R, Silence K, Pollet C, Cambillau C, de Haard H. Front Immunol 8 867 (2017)
  13. NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition. De Paula VS, Sgourakis NG, Francischetti IMB, Almeida FCL, Monteiro RQ, Valente AP. Blood 134 699-708 (2019)
  14. The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone. Larson SB, McPherson A. Curr Res Struct Biol 1 1-5 (2019)


Reviews citing this publication (24)

  1. Structural basis of substrate specificity in the serine proteases. Perona JJ, Craik CS. Protein Sci. 4 337-360 (1995)
  2. Snake venom proteins acting on hemostasis. Braud S, Bon C, Wisner A. Biochimie 82 851-859 (2000)
  3. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Lentz BR. Prog. Lipid Res. 42 423-438 (2003)
  4. Role of Na+ and K+ in enzyme function. Page MJ, Di Cera E. Physiol. Rev. 86 1049-1092 (2006)
  5. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Groenen LC, Nice EC, Burgess AW. Growth Factors 11 235-257 (1994)
  6. Exosite-driven substrate specificity and function in coagulation. Krishnaswamy S. J. Thromb. Haemost. 3 54-67 (2005)
  7. Molecular recognition in chemical and biological systems. Persch E, Dumele O, Diederich F. Angew. Chem. Int. Ed. Engl. 54 3290-3327 (2015)
  8. Factor X deficiency. Uprichard J, Perry DJ. Blood Rev. 16 97-110 (2002)
  9. Structural and energetic determinants of the S1-site specificity in serine proteases. Czapinska H, Otlewski J. Eur. J. Biochem. 260 571-595 (1999)
  10. Oral direct factor Xa inhibitors. Yeh CH, Fredenburgh JC, Weitz JI. Circ. Res. 111 1069-1078 (2012)
  11. The intriguing world of prothrombin activators from snake venom. Kini RM. Toxicon 45 1133-1145 (2005)
  12. Tick-derived Kunitz-type inhibitors as antihemostatic factors. Corral-Rodríguez MA, Macedo-Ribeiro S, Barbosa Pereira PJ, Fuentes-Prior P. Insect Biochem. Mol. Biol. 39 579-595 (2009)
  13. Determinants of specificity in coagulation proteases. Page MJ, Macgillivray RT, Di Cera E. J. Thromb. Haemost. 3 2401-2408 (2005)
  14. Prostaglandin H synthase: implications for membrane structure. Picot D, Garavito RM. FEBS Lett. 346 21-25 (1994)
  15. Coagulation factors and their inhibitors. Stubbs MT, Bode W. Curr. Opin. Struct. Biol. 4 823-832 (1994)
  16. Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition. Lin Z, Johnson ME. FEBS Lett. 370 1-5 (1995)
  17. Oral anticoagulants for Asian patients with atrial fibrillation. Sabir I, Khavandi K, Brownrigg J, Camm AJ. Nat Rev Cardiol 11 290-303 (2014)
  18. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Lee YK, Player MR. Med Res Rev 31 202-283 (2011)
  19. Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap. Yang Y, Lightstone FC, Wong SE. Expert Opin Drug Discov 8 277-287 (2013)
  20. The structure of thrombin, a chameleon-like proteinase. Bode W. J. Thromb. Haemost. 3 2379-2388 (2005)
  21. Targeting exosites on blood coagulation proteases. Monteiro RQ. An. Acad. Bras. Cienc. 77 275-280 (2005)
  22. Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis. Kontogiorgis CA, Hadjipavlou-Litina D. Med Res Rev 24 687-747 (2004)
  23. Proton Bridging in Catalysis by and Inhibition of Serine Proteases of the Blood Cascade System. Kovach IM. Life (Basel) 11 396 (2021)
  24. Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. Camire RM. J Thromb Thrombolysis 52 383-390 (2021)

Articles citing this publication (165)

  1. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Picot D, Loll PJ, Garavito RM. Nature 367 243-249 (1994)
  2. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. Nature 380 41-46 (1996)
  3. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK. Nature 367 532-538 (1994)
  4. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. Cell 82 131-141 (1995)
  5. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. Proc. Natl. Acad. Sci. U.S.A. 92 9796-9800 (1995)
  6. The 2.8 A crystal structure of Gla-domainless activated protein C. Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. EMBO J. 15 6822-6831 (1996)
  7. The ornithodorin-thrombin crystal structure, a key to the TAP enigma? van de Locht A, Stubbs MT, Bode W, Friedrich T, Bollschweiler C, Höffken W, Huber R. EMBO J. 15 6011-6017 (1996)
  8. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Dickinson CD, Kelly CR, Ruf W. Proc. Natl. Acad. Sci. U.S.A. 93 14379-14384 (1996)
  9. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. Protein Sci. 3 2254-2271 (1994)
  10. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Pike AC, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Proc. Natl. Acad. Sci. U.S.A. 96 8925-8930 (1999)
  11. The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities. Hof P, Mayr I, Huber R, Korzus E, Potempa J, Travis J, Powers JC, Bode W. EMBO J. 15 5481-5491 (1996)
  12. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Fuentes-Prior P, Noeske-Jungblut C, Donner P, Schleuning WD, Huber R, Bode W. Proc. Natl. Acad. Sci. U.S.A. 94 11845-11850 (1997)
  13. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Spraggon G, Phillips C, Nowak UK, Ponting CP, Saunders D, Dobson CM, Stuart DI, Jones EY. Structure 3 681-691 (1995)
  14. Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Mizuno H, Fujimoto Z, Atoda H, Morita T. Proc. Natl. Acad. Sci. U.S.A. 98 7230-7234 (2001)
  15. The molecular environment of the Na+ binding site of thrombin. Zhang E, Tulinsky A. Biophys. Chem. 63 185-200 (1997)
  16. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Structure 7 989-996 (1999)
  17. Crystal structure of the catalytic domain of human complement c1s: a serine protease with a handle. Gaboriaud C, Rossi V, Bally I, Arlaud GJ, Fontecilla-Camps JC. EMBO J. 19 1755-1765 (2000)
  18. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design. Engh RA, Brandstetter H, Sucher G, Eichinger A, Baumann U, Bode W, Huber R, Poll T, Rudolph R, von der Saal W. Structure 4 1353-1362 (1996)
  19. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Zhang E, St Charles R, Tulinsky A. J. Mol. Biol. 285 2089-2104 (1999)
  20. The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases. Parry MA, Jacob U, Huber R, Wisner A, Bon C, Bode W. Structure 6 1195-1206 (1998)
  21. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. Wei A, Alexander RS, Duke J, Ross H, Rosenfeld SA, Chang CH. J. Mol. Biol. 283 147-154 (1998)
  22. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. Renatus M, Engh RA, Stubbs MT, Huber R, Fischer S, Kohnert U, Bode W. EMBO J. 16 4797-4805 (1997)
  23. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin. Stubbs MT, Huber R, Bode W. FEBS Lett. 375 103-107 (1995)
  24. Ixolaris: a factor Xa heparin-binding exosite inhibitor. Monteiro RQ, Rezaie AR, Ribeiro JM, Francischetti IM. Biochem. J. 387 871-877 (2005)
  25. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. Hopfner KP, Brandstetter H, Karcher A, Kopetzki E, Huber R, Engh RA, Bode W. EMBO J. 16 6626-6635 (1997)
  26. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla). Kemball-Cook G, Johnson DJ, Tuddenham EG, Harlos K. J. Struct. Biol. 127 213-223 (1999)
  27. Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy. Freskgård PO, Olsen OH, Persson E. Protein Sci. 5 1531-1540 (1996)
  28. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. Burgering MJ, Orbons LP, van der Doelen A, Mulders J, Theunissen HJ, Grootenhuis PD, Bode W, Huber R, Stubbs MT. J. Mol. Biol. 269 395-407 (1997)
  29. Cleavage of the thrombin receptor: identification of potential activators and inactivators. Parry MA, Myles T, Tschopp J, Stone SR. Biochem. J. 320 ( Pt 1) 335-341 (1996)
  30. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Nar H, Bauer M, Schmid A, Stassen JM, Wienen W, Priepke HW, Kauffmann IK, Ries UJ, Hauel NH. Structure 9 29-37 (2001)
  31. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Katz BA, Mackman R, Luong C, Radika K, Martelli A, Sprengeler PA, Wang J, Chan H, Wong L. Chem. Biol. 7 299-312 (2000)
  32. Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Plescia J, Altieri DC. Biochem. J. 319 ( Pt 3) 873-879 (1996)
  33. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Peyvandi F, Menegatti M, Santagostino E, Akhavan S, Uprichard J, Perry DJ, Perkins SJ, Mannucci PM. Br. J. Haematol. 117 685-692 (2002)
  34. Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue. Estébanez-Perpiña E, Fuentes-Prior P, Belorgey D, Braun M, Kiefersauer R, Maskos K, Huber R, Rubin H, Bode W. Biol. Chem. 381 1203-1214 (2000)
  35. Structure and dynamics of zymogen human blood coagulation factor X. Venkateswarlu D, Perera L, Darden T, Pedersen LG. Biophys. J. 82 1190-1206 (2002)
  36. Structural basis of the zinc inhibition of human tissue kallikrein 5. Debela M, Goettig P, Magdolen V, Huber R, Schechter NM, Bode W. J. Mol. Biol. 373 1017-1031 (2007)
  37. Understanding protein-ligand interactions: the price of protein flexibility. Rauh D, Klebe G, Stubbs MT. J. Mol. Biol. 335 1325-1341 (2004)
  38. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Katz BA, Liu B, Barnes M, Springman EB. Protein Sci. 7 875-885 (1998)
  39. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. Jin L, Pandey P, Babine RE, Gorga JC, Seidl KJ, Gelfand E, Weaver DT, Abdel-Meguid SS, Strickler JE. J. Biol. Chem. 280 4704-4712 (2005)
  40. The critical role of the 185-189-loop in the factor Xa interaction with Na+ and factor Va in the prothrombinase complex. Rezaie AR, Kittur FS. J. Biol. Chem. 279 48262-48269 (2004)
  41. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Sperl S, Jacob U, Arroyo de Prada N, Stürzebecher J, Wilhelm OG, Bode W, Magdolen V, Huber R, Moroder L. Proc. Natl. Acad. Sci. U.S.A. 97 5113-5118 (2000)
  42. Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits. Takagi J, Beglova N, Yalamanchili P, Blacklow SC, Springer TA. Proc. Natl. Acad. Sci. U.S.A. 98 11175-11180 (2001)
  43. Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. Rao MS, Olson AJ. Proteins 34 173-183 (1999)
  44. A new structural class of serine protease inhibitors revealed by the structure of the hirustasin-kallikrein complex. Mittl PR, Di Marco S, Fendrich G, Pohlig G, Heim J, Sommerhoff C, Fritz H, Priestle JP, Grütter MG. Structure 5 253-264 (1997)
  45. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. Sturzebecher J, Kopetzki E, Bode W, Hopfner KP. FEBS Lett. 412 295-300 (1997)
  46. A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. Villoutreix BO, Teleman O, Dahlbäck B. J. Comput. Aided Mol. Des. 11 293-304 (1997)
  47. Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition. Rezaie AR, Manithody C, Yang L. J. Biol. Chem. 280 32722-32728 (2005)
  48. Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite. Monteiro RQ, Rezaie AR, Bae JS, Calvo E, Andersen JF, Francischetti IM. Protein Sci. 17 146-153 (2008)
  49. NMR solution structure of the recombinant tick anticoagulant protein (rTAP), a factor Xa inhibitor from the tick Ornithodoros moubata. Antuch W, Güntert P, Billeter M, Hawthorne T, Grossenbacher H, Wüthrich K. FEBS Lett. 352 251-257 (1994)
  50. Proposed structural models of the prothrombinase (FXa-FVa) complex. Autin L, Steen M, Dahlbäck B, Villoutreix BO. Proteins 63 440-450 (2006)
  51. Combined use of 13C chemical shift and 1H alpha-13C alpha heteronuclear NOE data in monitoring a protein NMR structure refinement. Celda B, Biamonti C, Arnau MJ, Tejero R, Montelione GT. J. Biomol. NMR 5 161-172 (1995)
  52. Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Duggan BM, Dyson HJ, Wright PE. Eur. J. Biochem. 265 539-548 (1999)
  53. Isoxazolines and isoxazoles as factor Xa inhibitors. Pruitt JR, Pinto DJ, Estrella MJ, Bostrom LL, Knabb RM, Wong PC, Wright MR, Wexler RR. Bioorg. Med. Chem. Lett. 10 685-689 (2000)
  54. Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa. Chen L, Manithody C, Yang L, Rezaie AR. Protein Sci. 13 431-442 (2004)
  55. Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor. Grzesiak A, Krokoszynska I, Krowarsch D, Buczek O, Dadlez M, Otlewski J. J. Biol. Chem. 275 33346-33352 (2000)
  56. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Taha MO, Qandil AM, Zaki DD, AlDamen MA. Eur J Med Chem 40 701-727 (2005)
  57. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, Hisamichi N, Sakai-Moritani Y, Kawasaki T, Matsumoto Y, Yanagisawa I. Bioorg. Med. Chem. 10 1509-1523 (2002)
  58. X-ray structure of antistasin at 1.9 A resolution and its modelled complex with blood coagulation factor Xa. Lapatto R, Krengel U, Schreuder HA, Arkema A, de Boer B, Kalk KH, Hol WG, Grootenhuis PD, Mulders JW, Dijkema R, Theunissen HJ, Dijkstra BW. EMBO J. 16 5151-5161 (1997)
  59. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding. Schmidt AE, Stewart JE, Mathur A, Krishnaswamy S, Bajaj SP. J. Mol. Biol. 350 78-91 (2005)
  60. Simulated annealing with restrained molecular dynamics using CONGEN: energy refinement of the NMR solution structures of epidermal and type-alpha transforming growth factors. Tejero R, Bassolino-Klimas D, Bruccoleri RE, Montelione GT. Protein Sci. 5 578-592 (1996)
  61. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Nienaber VL, Davidson D, Edalji R, Giranda VL, Klinghofer V, Henkin J, Magdalinos P, Mantei R, Merrick S, Severin JM, Smith RA, Stewart K, Walter K, Wang J, Wendt M, Weitzberg M, Zhao X, Rockway T. Structure 8 553-563 (2000)
  62. Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. Hsu HJ, Tsai KC, Sun YK, Chang HJ, Huang YJ, Yu HM, Lin CH, Mao SS, Yang AS. J. Biol. Chem. 283 12343-12353 (2008)
  63. Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. Murakami MT, Rios-Steiner J, Weaver SE, Tulinsky A, Geiger JH, Arni RK. J. Mol. Biol. 366 602-610 (2007)
  64. Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water. Salonen LM, Holland MC, Kaib PS, Haap W, Benz J, Mary JL, Kuster O, Schweizer WB, Banner DW, Diederich F. Chemistry 18 213-222 (2012)
  65. A fusion protein designed for noncovalent immobilization: stability, enzymatic activity, and use in an enzyme reactor. Stempfer G, Höll-Neugebauer B, Kopetzki E, Rudolph R. Nat. Biotechnol. 14 481-484 (1996)
  66. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. Buddai SK, Layzer JM, Lu G, Rusconi CP, Sullenger BA, Monroe DM, Krishnaswamy S. J. Biol. Chem. 285 5212-5223 (2010)
  67. Conserved water molecules in the specificity pocket of serine proteases and the molecular mechanism of Na+ binding. Krem MM, Di Cera E. Proteins 30 34-42 (1998)
  68. NMR structure determination of tick anticoagulant peptide (TAP). Lim-Wilby MS, Hallenga K, de Maeyer M, Lasters I, Vlasuk GP, Brunck TK. Protein Sci 4 178-186 (1995)
  69. Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin. Jayandharan G, Viswabandya A, Baidya S, Nair SC, Shaji RV, George B, Chandy M, Srivastava A. J. Thromb. Haemost. 3 1482-1487 (2005)
  70. Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin. Rana S, Yang L, Hassanian SM, Rezaie AR. J. Cell. Biochem. 113 977-984 (2012)
  71. Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. Fevig JM, Buriak J, Cacciola J, Alexander RS, Kettner CA, Knabb RM, Pruitt JR, Weber PC, Wexler RR. Bioorg. Med. Chem. Lett. 8 301-306 (1998)
  72. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Rezaie AR, Esmon CT. Eur. J. Biochem. 242 477-484 (1996)
  73. Mutation pattern in clinically asymptomatic coagulation factor VII deficiency. Bernardi F, Castaman G, Pinotti M, Ferraresi P, Di Iasio MG, Lunghi B, Rodeghiero F, Marchetti G. Hum. Mutat. 8 108-115 (1996)
  74. The structure of a 19-residue fragment from the C-loop of the fourth epidermal growth factor-like domain of thrombomodulin. Adler M, Seto MH, Nitecki DE, Lin JH, Light DR, Morser J. J. Biol. Chem. 270 23366-23372 (1995)
  75. A computer modeling study of the interaction between tissue factor pathway inhibitor and blood coagulation factor Xa. Yoneda T, Komooka H, Umeyama H. J Protein Chem 16 597-605 (1997)
  76. Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta. Schaeffer P, Mares AM, Dol F, Bono F, Herbert JM. Circ. Res. 81 824-828 (1997)
  77. Conformational rearrangements required of the V3 loop of HIV-1 gp120 for proteolytic cleavage and infection. Johnson ME, Lin Z, Padmanabhan K, Tulinsky A, Kahn M. FEBS Lett. 337 4-8 (1994)
  78. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification. Komoriya S, Kobayashi S, Osanai K, Yoshino T, Nagata T, Haginoya N, Nakamoto Y, Mochizuki A, Nagahara T, Suzuki M, Shimada T, Watanabe K, Isobe Y, Furugoori T. Bioorg. Med. Chem. 14 1309-1330 (2006)
  79. Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex. Yegneswaran S, Mesters RM, Fernández JA, Griffin JH. J. Biol. Chem. 279 49019-49025 (2004)
  80. Letter Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity. Grootenhuis PD, Westerduin P, Meuleman D, Petitou M, van Boeckel CA. Nat. Struct. Biol. 2 736-739 (1995)
  81. Reactivities of the S2 and S3 subsite residues of thrombin with the native and heparin-induced conformers of antithrombin. Rezaie AR. Protein Sci. 7 349-357 (1998)
  82. Restricted active site docking by enzyme-bound substrate enforces the ordered cleavage of prothrombin by prothrombinase. Hacisalihoglu A, Panizzi P, Bock PE, Camire RM, Krishnaswamy S. J. Biol. Chem. 282 32974-32982 (2007)
  83. Active site-independent recognition of substrates and product by bovine prothrombinase: a fluorescence resonance energy transfer study. Boskovic DS, Troxler T, Krishnaswamy S. J. Biol. Chem. 279 20786-20793 (2004)
  84. Determination of the P1', P2' and P3' subsite-specificity of factor Xa. Ludeman JP, Pike RN, Bromfield KM, Duggan PJ, Cianci J, Le Bonniec B, Whisstock JC, Bottomley SP. Int. J. Biochem. Cell Biol. 35 221-225 (2003)
  85. Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor. Carlsson K, Freskgård PO, Persson E, Carlsson U, Svensson M. Eur. J. Biochem. 270 2576-2582 (2003)
  86. Crystal structure analyses of uncomplexed ecotin in two crystal forms: implications for its function and stability. Shin DH, Song HK, Seong IS, Lee CS, Chung CH, Suh SW. Protein Sci. 5 2236-2247 (1996)
  87. Evolutionary conserved rigid module-domain interactions can be detected at the sequence level: the examples of complement and blood coagulation proteases. Gaboriaud C, Rossi V, Fontecilla-Camps JC, Arlaud GJ. J. Mol. Biol. 282 459-470 (1998)
  88. Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X. Bijak M, Ponczek MB, Nowak P. Int. J. Biol. Macromol. 65 129-135 (2014)
  89. Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity. Reyda S, Sohn C, Klebe G, Rall K, Ullmann D, Jakubke HD, Stubbs MT. J. Mol. Biol. 325 963-977 (2003)
  90. Structural resiliency of an EGF-like subdomain bound to its target protein, thrombin. Hrabal R, Komives EA, Ni F. Protein Sci. 5 195-203 (1996)
  91. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies. Galemmo RA, Maduskuie TP, Dominguez C, Rossi KA, Knabb RM, Wexler RR, Stouten PF. Bioorg. Med. Chem. Lett. 8 2705-2710 (1998)
  92. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Komoriya S, Haginoya N, Kobayashi S, Nagata T, Mochizuki A, Suzuki M, Yoshino T, Horino H, Nagahara T, Suzuki M, Isobe Y, Furugoori T. Bioorg. Med. Chem. 13 3927-3954 (2005)
  93. Structural models of the snake venom factor V activators from Daboia russelli and Daboia lebetina. Segers K, Rosing J, Nicolaes GA. Proteins 64 968-984 (2006)
  94. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. Bhongade BA, Gouripur VV, Gadad AK. Bioorg. Med. Chem. 13 2773-2782 (2005)
  95. A new factor X defect (factor X Padua 3): a compound heterozygous between true deficiency (Gly(380)-->Arg) and an abnormality (Ser(334)-->Pro). Vianello F, Lombardi AM, Boldrin C, Luni S, Girolami A. Thromb. Res. 104 257-264 (2001)
  96. Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. Rios-Steiner JL, Murakami MT, Tulinsky A, Arni RK. J. Mol. Biol. 371 774-786 (2007)
  97. Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA. Choi-Sledeski YM, Becker MR, Green DM, Davis R, Ewing WR, Mason HJ, Ly C, Spada A, Liang G, Cheney D, Barton J, Chu V, Brown K, Colussi D, Bentley R, Leadley R, Dunwiddie C, Pauls HW. Bioorg. Med. Chem. Lett. 9 2539-2544 (1999)
  98. Factor IX mutants with enhanced catalytic activity. Hartmann R, Dockal M, Kammlander W, Panholzer E, Nicolaes GA, Fiedler C, Rosing J, Scheiflinger F. J. Thromb. Haemost. 7 1656-1662 (2009)
  99. Molecular and structural advances in tissue factor-dependent coagulation. Kirchhofer D, Banner DW. Trends Cardiovasc. Med. 7 316-324 (1997)
  100. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. Bhunia SS, Roy KK, Saxena AK. J Chem Inf Model 51 1966-1985 (2011)
  101. Structure of the non-covalent complex of prothrombin kringle 2 with PPACK-thrombin. Arni RK, Padmanabhan K, Padmanabhan KP, Wu TP, Tulinsky A. Chem. Phys. Lipids 67-68 59-66 (1994)
  102. Synthesis, activity, and preliminary structure of the fourth EGF-like domain of thrombomodulin. Meininger DP, Hunter MJ, Komives EA. Protein Sci. 4 1683-1695 (1995)
  103. Trypsin mutants for structure-based drug design: expression, refolding and crystallisation. Rauh D, Reyda S, Klebe G, Stubbs MT. Biol. Chem. 383 1309-1314 (2002)
  104. Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor. Kadono S, Sakamoto A, Kikuchi Y, Oh-eda M, Yabuta N, Koga T, Hattori K, Shiraishi T, Haramura M, Kodama H, Esaki T, Sato H, Watanabe Y, Itoh S, Ohta M, Kozono T. Biochem. Biophys. Res. Commun. 324 1227-1233 (2004)
  105. Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate. Zaiss AK, Lawrence R, Elashoff D, Esko JD, Herschman HR. J. Biol. Chem. 286 24535-24543 (2011)
  106. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa. Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Nagamochi M, Kobayashi S, Komoriya S, Yokomizo A, Muto R, Yamaguchi M, Osanai K, Suzuki M, Kanno H. Bioorg. Med. Chem. 17 1193-1206 (2009)
  107. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-am idino- 2- naphthyl)propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis. Vaz RJ, McLean LR, Pelton JT. J. Comput. Aided Mol. Des. 12 99-110 (1998)
  108. Factor Va increases the affinity of factor Xa for prothrombin: a binding study using a novel photoactivable thiol-specific fluorescent probe. Yegneswaran S, Fernández JA, Griffin JH, Dawson PE. Chem. Biol. 9 485-494 (2002)
  109. Regulated cleavage of prothrombin by prothrombinase: repositioning a cleavage site reveals the unique kinetic behavior of the action of prothrombinase on its compound substrate. Bradford HN, Micucci JA, Krishnaswamy S. J. Biol. Chem. 285 328-338 (2010)
  110. The fifth epidermal growth factor-like domain of thrombomodulin does not have an epidermal growth factor-like disulfide bonding pattern. White CE, Hunter MJ, Meininger DP, Garrod S, Komives EA. Proc. Natl. Acad. Sci. U.S.A. 93 10177-10182 (1996)
  111. The functional significance of the autolysis loop in protein C and activated protein C. Yang L, Manithody C, Rezaie AR. Thromb. Haemost. 94 60-68 (2005)
  112. An oxyanion-hole selective serine protease inhibitor in complex with trypsin. Cui J, Marankan F, Fu W, Crich D, Mesecar A, Johnson ME. Bioorg. Med. Chem. 10 41-46 (2002)
  113. Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module. Hackeng TM, Dawson PE, Kent SB, Griffin JH. Biopolymers 46 53-63 (1998)
  114. Combinatorial enzyme design probes allostery and cooperativity in the trypsin fold. Page MJ, Di Cera E. J. Mol. Biol. 399 306-319 (2010)
  115. Determinants of the factor IX mutational spectrum in haemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein. Wacey AI, Krawczak M, Kakkar VV, Cooper DN. Hum. Genet. 94 594-608 (1994)
  116. Factor VIIa and the extracellular domains of human tissue factor form a compact complex: a study by X-ray and neutron solution scattering. Ashton AW, Kemball-Cook G, Johnson DJ, Martin DM, O'Brien DP, Tuddenham EG, Perkins SJ. FEBS Lett. 374 141-146 (1995)
  117. Functional and structural characterization of factor Xa dimer in solution. Chattopadhyay R, Iacob R, Sen S, Majumder R, Tomer KB, Lentz BR. Biophys. J. 96 974-986 (2009)
  118. Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells. Manithody C, Yang L, Rezaie AR. Biochemistry 51 2551-2557 (2012)
  119. Role of the N-terminal epidermal growth factor-like domain of factor X/Xa. Kittur FS, Manithody C, Rezaie AR. J. Biol. Chem. 279 24189-24196 (2004)
  120. The design of combinatorial libraries using properties and 3D pharmacophore fingerprints. Beno BR, Mason JS. Drug Discov. Today 6 251-258 (2001)
  121. The tick-derived anticoagulant madanin is processed by thrombin and factor Xa. Figueiredo AC, de Sanctis D, Pereira PJ. PLoS ONE 8 e71866 (2013)
  122. Approaches to selective peptidic inhibitors of factor Xa. Bromfield KM, Quinsey NS, Duggan PJ, Pike RN. Chem Biol Drug Des 68 11-19 (2006)
  123. Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille). Bezeaud A, Miyata T, Helley D, Zeng YZ, Kato H, Aillaud MF, Juhan-Vague I, Guillin MC. Eur. J. Biochem. 234 140-147 (1995)
  124. Mutagenesis studies toward understanding allostery in thrombin. Qureshi SH, Yang L, Manithody C, Iakhiaev AV, Rezaie AR. Biochemistry 48 8261-8270 (2009)
  125. Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Becker MR, Ewing WR, Davis RS, Pauls HW, Ly C, Li A, Mason HJ, Choi-Sledeski YM, Spada AP, Chu V, Brown KD, Colussi DJ, Leadley RJ, Bentley R, Bostwick J, Kasiewski C, Morgan S. Bioorg. Med. Chem. Lett. 9 2753-2758 (1999)
  126. Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X. Isshiki I, Favier R, Moriki T, Uchida T, Ishihara H, Van Dreden P, Murata M, Ikeda Y. Blood Coagul. Fibrinolysis 16 9-16 (2005)
  127. Insights into the substrate specificity of a novel snake venom serine peptidase by molecular modeling. Vitorino-Cardoso AF, Pereira Ramos OH, Homsi-Brandeburgo MI, Selistre-de-Araujo HS. Comp. Biochem. Physiol. B, Biochem. Mol. Biol. 144 334-342 (2006)
  128. Phosphatidylserine-induced factor Xa dimerization and binding to factor Va are competing processes in solution. Majumder R, Koklic T, Rezaie AR, Lentz BR. Biochemistry 52 143-151 (2013)
  129. Self-activating factor X derivative fused to the C-terminus of a cellulose-binding module: Production and properties. Kwan E, Guarna MM, Boraston AB, Gilkes NR, Haynes CA, Kilburn DG, Warren RA. Biotechnol. Bioeng. 79 724-732 (2002)
  130. Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors. Heinelt U, Herok S, Matter H, Wildgoose P. Bioorg. Med. Chem. Lett. 11 227-230 (2001)
  131. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand. Galemmo RA, Wells BL, Rossi KA, Alexander RS, Dominguez C, Maduskuie TP, Stouten PF, Wright MR, Aungst BJ, Wong PC, Knabb RM, Wexler RR. Bioorg. Med. Chem. Lett. 10 301-304 (2000)
  132. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies. Sperl S, Bergner A, Stürzebecher J, Magdolen V, Bode W, Moroder L. Biol. Chem. 381 321-329 (2000)
  133. A novel type I factor X variant (factor X Cys350Phe) due to loss of a disulfide bond in the catalytic domain. Vianello F, Lombardi AM, Bello FD, Palù G, Zanon E, Girolami A. Blood Coagul. Fibrinolysis 14 401-405 (2003)
  134. A structural network associated with the kallikrein-kinin and renin-angiotensin systems. Stoka V, Turk V. Biol. Chem. 391 443-454 (2010)
  135. Comment Big rigs in blood coagulation. Bazan JF. Nature 380 21-23 (1996)
  136. Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. Takano Y, Koizumi M, Takarada R, Kamimura MT, Czerminski R, Koike T. J. Mol. Graph. Model. 22 105-114 (2003)
  137. Engineering factor X fusions for expression in Pichia pastoris. Guarna MM, Côté HC, Amandoron EA, MacGillivray RT, Warren RA, Kilburn DG. Ann. N. Y. Acad. Sci. 799 397-400 (1996)
  138. Exploration of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations. Wang JF, Hao P, Li YX, Dai JL, Li X. J Mol Model 18 2717-2725 (2012)
  139. Factor X fusion proteins: improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein. Guarna MM, Côté HC, Kwan EM, Rintoul GL, Meyhack B, Heim J, MacGillivray RT, Warren RA, Kilburn DG. Protein Expr. Purif. 20 133-141 (2000)
  140. Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study. Fraternali F, Do QT, Doan BT, Atkinson RA, Palmas P, Sklenar V, Safar P, Wildgoose P, Strop P, Saudek V. Proteins 30 264-274 (1998)
  141. Novel benzo-fused lactam scaffolds as factor Xa inhibitors. Tamura SY, Goldman EA, Bergum PW, Semple JE. Bioorg. Med. Chem. Lett. 9 2573-2578 (1999)
  142. Factor Xa: simulation studies with an eye to inhibitor design. Daura X, Haaksma E, van Gunsteren WF. J. Comput. Aided Mol. Des. 14 507-529 (2000)
  143. Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain. Marchetti G, Castaman G, Pinotti M, Lunghi B, Di Iasio MG, Ruggieri M, Rodeghiero F, Bernardi F. Br. J. Haematol. 90 910-915 (1995)
  144. One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa. Morishita E, Yamaguchi K, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, Kato M, Nakao S. Int. J. Hematol. 73 390-392 (2001)
  145. Syntheses and selective inhibitory activities of terphenyl-bisamidines for serine proteases. von der Saal W, Engh RA, Eichinger A, Gabriel B, Kucznierz R, Sauer J. Arch. Pharm. (Weinheim) 329 73-82 (1996)
  146. 2-aminomethylphenylamine as a novel scaffold for factor Xa inhibitor. Mochizuki A, Nagata T, Kanno H, Suzuki M, Ohta T. Bioorg. Med. Chem. 19 1623-1642 (2011)
  147. Characterization of the protein Z-dependent protease inhibitor interactive-sites of protein Z. Qureshi SH, Lu Q, Manithody C, Yang L, Rezaie AR. Biochim. Biophys. Acta 1844 1631-1637 (2014)
  148. Crystallization and preliminary X-ray analysis of active site-inhibited human coagulation factor VIIa (des-Gla). Johnson DJ, Nugent PG, Tuddenham EG, Harlos K, Kemball-Cook G. J. Struct. Biol. 125 90-93 (1999)
  149. Deuterium solvent isotope effect and proton-inventory studies of factor Xa-catalyzed reactions. Zhang D, Kovach IM. Biochemistry 45 14175-14182 (2006)
  150. Factor Va alters the conformation of the Na+-binding loop of factor Xa in the prothrombinase complex. Yang L, Manithody C, Qureshi SH, Rezaie AR. Biochemistry 47 5976-5985 (2008)
  151. Investigation of factor Xa inhibitors containing non-amidine S1 elements. Franciskovich JB, Masters JJ, Tinsley JM, Craft TJ, Froelich LL, Gifford-Moore DS, Klimkowski VJ, Smallwood JK, Smith GF, Smith T, Towner RR, Weir LC, Wiley MR. Bioorg. Med. Chem. Lett. 15 4838-4841 (2005)
  152. Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa. Yang L, Rezaie AR. J. Biol. Chem. 288 12692-12698 (2013)
  153. Structure of human factor VIIa-soluble tissue factor with calcium, magnesium and rubidium. Vadivel K, Schmidt AE, Cascio D, Padmanabhan K, Krishnaswamy S, Brandstetter H, Bajaj SP. Acta Crystallogr D Struct Biol 77 809-819 (2021)
  154. Substrate turnover and inhibitor binding as selection parameters in directed evolution of blood coagulation factor Xa. Lorentsen RH, Møller CH, Etzerodt M, Thøgersen HC, Holtet TL. Org. Biomol. Chem. 1 1657-1663 (2003)
  155. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism. Andersen JF, Lei H, Strayer EC, Kanai T, Pham V, Pan XZ, Alvarenga PH, Gerber GF, Asojo OA, Francischetti IMB, Brodsky RA, Valenzuela JG, Ribeiro JMC. Blood 141 3109-3121 (2023)
  156. Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X. Chafa O, Tagzirt M, Tapon-Bretaudière J, Reghis A, Fischer AM, LeBonniec BF. Thromb. Res. 124 144-148 (2009)
  157. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. Castro-López V, Harris LF, O'Donnell JS, Killard AJ. Anal Bioanal Chem 399 691-700 (2011)
  158. Mapping specificity, cleavage entropy, allosteric changes and substrates of blood proteases in a high-throughput screen. Uliana F, Vizovišek M, Acquasaliente L, Ciuffa R, Fossati A, Frommelt F, Goetze S, Wollscheid B, Gstaiger M, De Filippis V, Auf dem Keller U, Aebersold R. Nat Commun 12 1693 (2021)
  159. Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene. Lu Q, Yang L, Manithody C, Wang X, Rezaie AR. Thromb. Res. 134 1103-1109 (2014)
  160. Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites. Singh N, Briggs JM. Biopolymers 89 1104-1113 (2008)
  161. Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study. Vadivel K, Schreuder HA, Liesum A, Schmidt AE, Goldsmith G, Bajaj SP. J Thromb Haemost 17 574-584 (2019)
  162. Aspartate/asparagine-β-hydroxylase crystal structures reveal an unexpected epidermal growth factor-like domain substrate disulfide pattern. Pfeffer I, Brewitz L, Krojer T, Jensen SA, Kochan GT, Kershaw NJ, Hewitson KS, McNeill LA, Kramer H, Münzel M, Hopkinson RJ, Oppermann U, Handford PA, McDonough MA, Schofield CJ. Nat Commun 10 4910 (2019)
  163. Reversible modulation of human factor Xa activity with phosphonate esters: media effects. Enyedy EJ, Kovach IM. Bioorg. Med. Chem. 8 549-556 (2000)
  164. Role of P2 glycine in determining the specificity of antithrombin reaction with coagulation proteases. Yang L, Qureshi SH, Manithody C, Rezaie AR. Biochem. Biophys. Res. Commun. 389 162-167 (2009)
  165. Thrombolysis by chemically modified coagulation factor Xa. Pryzdial EL, Meixner SC, Talbot K, Eltringham-Smith LJ, Baylis JR, Lee FM, Kastrup CJ, Sheffield WP. J. Thromb. Haemost. 14 1844-1854 (2016)


Related citations provided by authors (3)

  1. Three-dimensional structure of the apo form of the N-terminal EGF-like module of blood coagulation factor X as determined by NMR spectroscopy and simulated folding.. Ullner M, Selander M, Persson E, Stenflo J, Drakenberg T, Teleman O Biochemistry 31 5974-83 (1992)
  2. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM J Mol Biol 221 1379-93 (1991)
  3. Comparative model-building of the mammalian serine proteases.. Greer J J Mol Biol 153 1027-42 (1981)

Quick links